Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
NCT00111774 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2013-05-14
Summary
The purpose of this study is to determine if ABX-EGF is safe and efficacious in patients with metastatic colorectal cancer.
Conditions
- Colorectal Cancer
- Carcinoma
Interventions
- DRUG
-
ABX-EGF
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-03-31
More Related Trials
-
Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
NCT00327119 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
NCT00083616 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
NCT05239650 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
NCT00004879 ·Status: COMPLETED ·Phase: PHASE1
-
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
NCT00460603 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
NCT00177307 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
NCT00114946 ·Status: TERMINATED ·Phase: PHASE4
-
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
NCT00005085 ·Status: COMPLETED ·Phase: PHASE2
-
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
NCT01189903 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
NCT01730586 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Low Dose Metronomic Poly-chemotherapy for Metastatic CRC
NCT02280694 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer
NCT03017807 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
NCT01490866 ·Status: COMPLETED ·Phase: PHASE2
-
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
NCT01103323 ·Status: COMPLETED ·Phase: PHASE3
-
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
NCT00017082 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)
NCT00997685 ·Status: UNKNOWN ·Phase: PHASE2
-
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
NCT06011772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
NCT00779311 ·Status: TERMINATED ·Phase: PHASE1
-
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
NCT04853043 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
NCT00102024 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT02096354 ·Status: COMPLETED ·Phase: PHASE2